NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript
Analyzing First Choice Healthcare Solutions (OTCMKTS:FCHS) & NeuroOne Medical Technologies (NASDAQ:NMTC)
NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript
Brokerages Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) PT at $1.98
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript
NeuroOne Medical Technologies (NASDAQ:NMTC) versus Aclarion (NASDAQ:ACON) Head to Head Contrast
Contrasting NeuroOne Medical Technologies (NASDAQ:NMTC) and Cannlabs (OTCMKTS:CANL)
Best Momentum Stocks to Buy for January 6th
New Strong Buy Stocks for January 6th
NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript
NeuroOne Medical Technologies Corporation - Special Call
NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
NeuroOne Medical Technologies Corporation (NMTC) Q2 2025 Earnings Call Transcript
NeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%
NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor
NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference
NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne® Issues Letter to Shareholders
NeuroOne® OneRF® Technology Success Story Featured on Fox News
Nasdaq Dips 5%; NeuroOne Medical Technologies Shares Plummet
NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace
NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne® to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
NeuroOne Medical Technologies Corporation (NMTC) Q1 2025 Earnings Call Transcript
NeuroOne® Reports First Quarter Fiscal Year 2025 Financial Results and Provides Corporate Update
NeuroOne® to Report First Quarter Fiscal Year 2025 Financial Results on Wednesday, February 12 at 8:30 a.m. Eastern Time
NeuroOne® Regains Compliance with Nasdaq Listing Requirements
NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million
Stock Picks From Seeking Alpha's December 2024 New Analysts
NeuroOne® Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST
NeuroOne Medical Technologies Corporation (NMTC) Q4 2024 Earnings Call Transcript
NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025
NeuroOne Medical Technologies: A Small-Cap Electrode Technology Play With Multiple Catalysts Ahead
NeuroOne Medical Technologies Corporation to Present at November 21st Virtual Investor Summit Microcap Event
NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System